电邮这篇文章 Implantation of the paclitaxel-eluting stent Apollo in patients with stable angina pectoris: Long-term angiographic and clinical results
- 作者: Batyraliev TA1, Fetser DV2, Samko AN3, Sidorenko BA4
-
隶属关系:
- Sani Konukogly Medical Center, Gaziantep, Turkey
- Regional Clinical Hospital Hospital, Lipetsk
- A. L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow
- Training and Research Center, Department for Presidential Affairs of the Russian Federation, Moscow
- 期: 卷 82, 编号 8 (2010)
- 页面: 20-23
- 栏目: Editorial
- URL: https://bakhtiniada.ru/0040-3660/article/view/30615
- ID: 30615
如何引用文章
全文:
详细
Aim: to assess the long-term angiographic and clinical results of percutaneous coronary interventions (PCI) with implantation of the drug-eluting stent (DES) Apollo in patients with stable angina pectoris.
Subjects and methods. The study enrolled 48 patients with stable angina who had been implanted with 59 stents. A follow-up of the patients lasted 12 months.
Results. The intervention was successful in 100% patients. Following 12 months, 81.3% of the patients underwent angiography that demonstrated that the vascular diameter decreased by 0.32±0.45 mm and the rate of restenosis was reduced by only 5.3%. The frequency of evident cardiac complications over 12 months was as high as 11.6%.
Conclusion. The DES Apollo provides a way of safely performing PCI, by achieving a high of angiographic success rate. The application of this stent yields long-term good angiographic and clinical results in patients with stable angina pectoris.
Subjects and methods. The study enrolled 48 patients with stable angina who had been implanted with 59 stents. A follow-up of the patients lasted 12 months.
Results. The intervention was successful in 100% patients. Following 12 months, 81.3% of the patients underwent angiography that demonstrated that the vascular diameter decreased by 0.32±0.45 mm and the rate of restenosis was reduced by only 5.3%. The frequency of evident cardiac complications over 12 months was as high as 11.6%.
Conclusion. The DES Apollo provides a way of safely performing PCI, by achieving a high of angiographic success rate. The application of this stent yields long-term good angiographic and clinical results in patients with stable angina pectoris.
作者简介
T Batyraliev
Sani Konukogly Medical Center, Gaziantep, Turkey
Email: talantbekb@yahoo,com
Sani Konukogly Medical Center, Gaziantep, Turkey
D Fetser
Regional Clinical Hospital Hospital, Lipetsk
Email: fettser@gmail.com
Regional Clinical Hospital Hospital, Lipetsk
A Samko
A. L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow
Email: samkoan@mail.ru
A. L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies, Moscow
B Sidorenko
Training and Research Center, Department for Presidential Affairs of the Russian Federation, Moscow
Email: sid_b_a@mail.ru
Training and Research Center, Department for Presidential Affairs of the Russian Federation, Moscow
参考
- Беленков Ю. Н. Лечение ишемической болезни сердца: старые традиции и новые тенденции. Тер. арх. 2005; 9: 5- 8.
- Sigwart U., Puel J., Mirkovitch V. et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N. Engl. J. Med. 1987; 316: 701-706.
- Radke P. W., Kaiser A., Frost C., Sigwart U. Outcome after treatment of coronary in-stent restenosis; results from a systematic review using meta-analysis techniques. Eur. Heart J. 2003; 24: 266-273.
- Lowe H. C., Oesterle S. N., Khachigian L. M. Coronary in-stent restenosis: current status and future strategies. J. Am. Coll. Cardiol. 2002; 39: 183-193.
- Жамгыргиев Ш. Т., Фетцер Д. В., Першуков И. В. и др. Клиническое значение стентов с лекарственным покрытием. Тер. арх. 2007; 9: 79-84.
- Kastrati A., Dibra A., Eberle S., et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. J. A. M. A. 2005; 294: 819-825.
- Bokeriya L. A., Sengul H., Guseyinov E. A. et al. Stents which are used with polymer technology and bioabsobable stents. Turk. J. Invest. Cardiol. 2007; 11: 156-162.
- Babapulle M. N., Joseph L., Belisle P. et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364: 583-591.
- Kotani J., Awata M., Nanto S. et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic ?ndings. J. Am. Coll. Cardiol. 2006; 47: 2108-2111.
- Wessely R., Kastrati A., Sch?mig A. Late restenosis in patients receiving a polymer coated sirolimus-eluting stent. Ann. Intern. Med. 2005; 143: 392-394.
- Joner M., Finn A. V., Farb A. et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 2006; 48: 193-202.
- Psterer M., Brunner-La Rocca H. P., Buser P. T. et al. BASKET investigators. Late clinical events after clopidogrel discontinuation may limit the bene?t of drug-eluting stents. J. Am. Coll. Cardiol. 2006; 48: 2584-2591.
- King S. B., Aversano T., Ballard W. L. et al. ACCF/AHA/ SCAI 2007 update of the clinical competence statement on cardiac interventional procedures. Circulation 2007; 116: 98- 124.
- Serruys P. W., Kutryk M. J. B. Handbook of coronary stents. 3-rd ed. London: Martin Dunitz; 2000.
- Батыралиев Т. А., Фетцер Д. В., Преображенский Д. В., Сидоренко Б. А. Проблема осложнений при чрескожных коронарных вмешательствах. Часть I. Характер и частота осложнений. Кардиология 2008; 48 (1): 81-87.
- Sigwart U., Urban P., Golf S. et al. Emergency stenting for acute occlusion after coronary balloon angioplasty. Circulation 1988; 78: 1121-1127.
- Serruys P. W., de Jaegere P., Kiemeneij F. et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. N. Engl. J. Med. 1994; 331: 489-495.
- Baim D. S., Levine M. J., Leon M. B. et al. Management of restenosis within the Palmaz-Schatz coronary stent: the U. S. multicenter experience - the U. S. Palmaz-Schatz Stent Investigators. Am. J. Cardiol. 1993; 71: 364-366.
- Antoniucci D., Bartorelli A., Valenti R. et al. Clinical and angiographic outcome after coronary arterial stenting with the carbostent. Am. J. Cardiol. 2000; 85: 821-825.
- Boland J. L., Corbeij H., Van Der Giessen W. et al. Multicenter evaluation of the phosphorylcholinecoated biodivYsio stent in short de novo coronary lesions: The SOPHOS study. Int. J. Cardiovasc. Intervent. 2000; 3: 215--225.
- Guarda E., Marchant E., Fajuri A. et al. Oral rapamycin to prevent human coronary stent restenosis: A pilot study. Am. Heart J. 2004; 148(2): e9.
- Takagi T., Akasaka T., Yamamuro A. et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with noninsulin dependent diabetes mellitus. J. Am. Coll. Cardiol. 2000; 36: 1529-1535.
- Holmes D., Fitzgerald P., Goldberg S. et al. The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: a double-blind, placebo-controlled trial. Am. Heart J. 2000; 139: 23-31.
- Dobesh P. P., Stacy Z. A., Ansara A. J. et al. Drug-eluting stents: A mechanical and pharmacologic approach to coronary artery disease. Pharmacotherapy 2004; 24 (11): 1554-1577.
- Sasseen B., Costa M. A. A new stent revolution: Drug-eluting stents. In: American college of cardiology. 52nd Annual scientific session. Chicago; 2003.
- Батыралиев Т. А., Першуков И. В. Обзор клинических исследований по ишемической болезни сердца и ее инвазивному лечению. Кардиология 2002; 5: 68-70.
- Rensing B. J., Vos J., Smits P. C. et al. Coronary restenosis elimination with a sirolimus eluting stent. First European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur. Heart J. 2001; 22: 2125-2130.
- Ellis S. G., Popma J. J., Lasala J. M. et al. Relationship between angiographic late loss and target lesion revascularization after coronary stentimplantation: analysis from the TAXUS-IV trial. J. Am. Coll. Cardiol. 2005; 45: 1193-1200.
- Windecker S., Remondino A., Eberli F. R. et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N. Engl. J. Med. 2005; 353: 653-662.
- Dibra A., Kastrati A., Mehilli J. et al. Paclitaxel-eluting stents compared with sirolimus-eluting stents for the prevention of restenosis in diabetic patients with coronary artery disease. N. Engl. J. Med. 2005; 353: 663-670.
- Sousa J. E., Costa M. A., Abizaid A. et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation 2005; 111: 2326-2329.
- Hermiller J. B., Raizner A., Cannon L. et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J. Am. Coll. Cardiol. 2005; 45: 1172-1179.
- Abizaid A., Costa M. A., Blanchard D. et al. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial. Eur. Heart J. 2004; 25: 107- 112.
- Schofer J., Schluter M., Gershlick A. H. et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-1099.
补充文件
